

Naam:	Karper
Voornamen:	Jacobus Cornelis (roepnaam Jacco)
Titels:	doctor
2019	EACVI cardiale MRI, level 2 gecertificeerd
2019	European Society of Human Genetics Training Course on Cardiogenetics, Antwerpen
2019	Aandachtsjaar cardiologie; niet-invasieve beeldvorming en cardiogenetica/erfelijke hartziekten
2018	EACVI TOE examen
2018	SCCT cardiovasculaire CT, level 2 gecertificeerd
2018	EACVI TTE, level 2 gecertificeerd
2018	ESC Europees examen in algemene cardiologie
2018	6 ^e AIOS talentenklas, Ede (Academie Medisch Specialisten)
2017 - 2018	B-jaar cardiologie opleiding MCL, Leeuwarden
2014 - 2016	Vooropleiding Interne geneeskunde, Martini ziekenhuis Groningen
2014	Promotie Universiteit Leiden; Damage Associated Molecular Patterns and Toll Like Receptors in inflammation mediated vascular remodeling
2013	AIOS cardiologie, UMCG, Groningen
2013	Artsexamen, <i>cum laude</i> , LUMC, Leiden
2012 - 2013	Coschappen, LUMC, Leiden
2011	EAS, Summer School Inflammation and Cardiovascular Disease, Obergurgl, Oostenrijk
2010	Deel promotieonderzoek aan PARis Cardiovascular Center (PARCC), Hopital Europeen Georges Pompidou/INSERM, Parijs, Frankrijk. prof. Alain Tedgui (Parijs) en prof. Ziad Mallat (Parijs/Cambridge)
2009	Vascular Biology Course, Nederlandse Hartstichting
2009	Drug Discovery & Development Cycle Course, TIPharma, Zeist
2008	Business & Entrepreneurial Skills Course, TIPharma, Zeist
2008 - 2012	Promotie onderzoek rol Toll Like Receptors in vasculaire remodeling TNO/LUMC Leiden (promotores prof. dr. P.H.A. Quax, prof. dr. W.J. Jukema)
2004 - 2007	Intensive Care-ondersteuner op de LUMC Thorax Intensive Care (Joshua's) te Leiden.
2003 - 2007	Doctoraal Geneeskunde LUMC Leiden
2002 - 2003	Biofarmaceutische wetenschappen, Universiteit Leiden
1996 - 2002	VWO, CSG Liudger, Drachten

Full papers

1. Genetically Determined ABO Blood Group and its Associations With Health and Disease. Groot HE, Villegas Sierra LE, Said MA, Lipsic E, Karper JC, van der Harst P. *ATVB* 2020.
2. Leukocyte profiles across the cardiovascular disease continuum: A population-based cohort study. Groot HE, van Blokland IV, Lipsic E, Karper JC, van der Harst P. *JMCC* 2019
3. Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Groot HE, Al Ali L, van der Horst ICC, Schurer RAJ, van der Werf HW, Lipsic E, van Veldhuisen DJ, Karper JC, van der Harst P. *Clin Res Cardiol* 2019
4. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Hartman MHT, Groot HE, Leach IM, Karper JC, van der Harst P. *Trends Cardiovasc Med.* 2018
5. The epigenetic factor PCAF regulates vascular inflammation and is essential for intimal hyperplasia development. de Jong RCM, Ewing MM, de Vries MR, Karper JC, Bastiaansen AJNM, Peters HAB, Baghana F, van den Elsen PJ, Gongora C, Jukema JW, Quax PHA. *Plos One* 2017
6. High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction. Groot HE, Karper JC, Lipsic E, van Veldhuisen DJ, van der Horst ICC, van der Harst. *International Journal of Cardiology* 2017
7. Flank pain caused by a renal artery dissection Karper JC, Janssen WM, Breek JC, Oosterhof-Berkas R, Gravendeel J, Kremer Hovinga TK. *NTVG* 2017
8. Deficiency of the TLR4 analogue RP105 aggravates vein graft disease by inducing a pro-inflammatory response. Wezel A, de Vries MR, Maassen JM, Kip P, Peters EA, Karper JC, Kuiper J, Bot I, Quax PH. *Scientific Reports.* 2016
9. BNP in heart failure even leucocytes cannot escape its influence. Editorial. Karper JC, Westenbrink BD. *Eur J Heart Fail.* 2015
10. RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner. Wezel A, van der Velden D, Maassen JM, Lagraauw HM, de Vries MR, Karper JC, Kuiper J, Bot I, Quax PH. *Atherosclerosis.* 2015
11. RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. Karper J.C, Louwe M.C, de Vries M.R, Bastiaansen A.J.N.M, van der Hoorn J.W.A, Willems van Dijk K, Rensen P.C.N, Steendijk P, Smit J.W.A, Quax P.H.A. *International Journal of Cardiology*

12. TLR4 accessory molecule RP105 (CD180) regulates monocyte-driven arteriogenesis in a murine hind limb ischemia model. Antonius J.N.M. Bastiaansen, Jacco C. Karper, Hetty C. de Boer, Sabine M.J. Welten, Rob C.M. de Jong, Erna A.B. Peters, Margreet R. de Vries, Annemarie M. van Oeveren-Rietdijk, A.J. van Zonneveld, Jaap F. Hamming, A. Yaël Nossent, Paul H.A. Quax. *Plos One* 2014
13. An unexpected intriguing effect of TLR regulator RP105 (CD180) on atherosclerosis formation with alterations on B cell activation Karper J.C., de Jager S.C.A., Ewing M.M., de Vries M.R., Bot I., van Santbrink P.J., Redeker A., Mallat Z., Binder C.J., Arens R., Jukema J.W., Kuiper J., Quax P.H.A. *Arterioscler Thromb Vasc Biol* 2013
14. TLR Accessory Molecule RP105 (CD180) Is Involved in Post-Interventional Vascular Remodeling and Soluble RP105 Modulates Neointima Formation. Karper JC, Ewing MM, de Vries MR, de Jager SC, Peters EA, de Boer HC, van Zonneveld AJ, Kuiper J, Huizinga EG, Brondijk TH, Jukema JW, Quax PH. *PLoS One*. 2013 Jul 2;8(7):e67923.
15. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, Jukema JW, Quax PH. *Int J Cardiol*. 2013 Jan 22.
16. Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Karper JC, Ewing MM, Habets KL, de Vries MR, Peters EA, van Oeveren-Rietdijk AM, de Boer HC, Hamming JF, Kuiper J, Kandimalla ER, La Monica N, Jukema JW, Quax PH. *Arterioscler Thromb Vasc Biol*. 2012 Aug;32(8):e72-80.
17. Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice. Ewing MM, Karper JC, Sampietro ML, de Vries MR, Pettersson K, Jukema JW, Quax PH. *Atherosclerosis*. 2012 Apr;221(2):333-40.
18. Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis. Karper JC, Ewing MM, Jukema JW, Quax PH. *Biomark Med*. 2012 Feb;6(1):53-66.
19. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefler IE, Doevendans PA, Pasterkamp G, de Kleijn DP. *Circ Res*. 2011 Mar 4;108(5):582-92.
20. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Karper JC, de Vries MR, van den Brand BT, Hoefler IE, Fischer JW, Jukema JW, Niessen HW, Quax PH. *Arterioscler Thromb Vasc Biol*. 2011 May;31(5):1033-40.
21. In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor. Eefting D, de Vries MR, Grimbergen JM, Karper JC, van Bockel JH, Quax PH. *J Vasc Surg*. 2010 Feb;51(2):429-37.
22. Optimizing Natural Occurring IgM Antibodies for Therapeutic Use: Inflammatory Vascular Disease Treatment with Anti-Phosphorylcholine IgG. M.M. Ewing, J.C. Karper, M.R. de Vries, M. Nordzell, S.A.P. Karabina, R. Atout, D. Sexton, H. Lettesjö, I. Dahlbom, O. Camber, J. Frostegård, J. Kuiper, E. Ninio, J.W. Jukema, K. Pettersson, P.H.A. Quax.

Bookchapters

Small animal models to study restenosis and effects of (local) drug therapy. Karper JC, Ewing MM, de Vries MR, Jukema JW, Quax PHA. *Coronary stent restenosis*. Editor: IC Tintoiu. Bucharest: The Publishing House of the Romanian Academy, 2011.

Proefschrift:

Damage Associated Molecular Patterns and Toll Like Receptors in inflammation mediated vascular remodeling, Leiden, 2014